{
  "documentMetadata": {
    "title": "Respiratory Syncytial Virus, RSV",
    "sourceFile": "Respiratory Syncytial Virus, RSV.pdf",
    "lastUpdated": "2024-07-10"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Respiratory Syncytial Virus (RSV) is a major cause of morbidity in neonates and infants.",
        "In adults, RSV accounted for 10.6% of hospitalizations for pneumonia, 11.4% for chronic obstructive pulmonary disease (COPD), 7.2% for asthma & 5.4% for congestive heart failure (CHF) in patients age >65 years, BMJ 2019 Sep 10;366:15021,",
        "Impact and burden in older adults similar or worse than to influenza Clin Infect Dis 76:1980 2023; N Engl J Med 352:1749, 2005.",
        "RSV peak incidence is in winter (e.g., December 2023 to April 2024 RSV season). Check with Public Health Departments for incidence in local region",
        "Recap of 2022-2023 winter season:",
        "Concurrently circulating respiratory viruses of particular concern: Influenza and COVID-19.",
        "CDC HAN 0479 (11/4/2022) - increased respiratory virus activity, including RSV, influenza and COVID-19",
        "In childen RSV accounted for 27% of hospitalizations for pneumonia (N Engl J Med 372:835 2015)",
        "RSV caused 11% of clinically important respiratory illnesses in military recruits, Clin Infect Dis 41:311, 2005.",
        "Lower respiratory infection in hematopoietic cell transplant (HCT) patients have high morbidity and mortality, particularly in first 6 months. BMJ 2019 Sep 10;366:15021; Blood 117:2755, 2011; Clin Infect Dis 56:258, 2013.",
        "New direct antiviral drugs under development showed promise but development halted on several. J Infect Dis 2020:222;1417-21; N Engl J Med 371:711-22, 2014; N Engl J Med 373:2048-58, 2015",
        "Prevention with palivizumab is indicated for (monthly doses required during RSV season):",
        "Children age <24 months with chronic lung disease of prematurity (formerly bronchopulmonary dysplasia) requiring supplemental oxygen.",
        "Premature infants (<32 weeks gestation) and age <6 months at the start of RSV season.",
        "Children with selected congenital heart diseases.",
        "Nirsevimab, a long acting monoclonal antibody was licensed in many countries in summer 2023. It is expected to be available fall of 2023 and will replace palivizumab",
        "Expected indications for nirsevimab:",
        "All infants during their first RSV season (i.e. administer in fall for infants born April-September; administer at birth for infants born October-March)",
        "Select high risk infants in their second RSV season"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Respiratory syncytial virus (RSV)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Treatment:"
        },
        {
          "type": "procedure",
          "name": "Hydration, supplemental oxygen."
        },
        {
          "type": "paragraph",
          "text": "Routine use of Ribavirin is not recommended outside of HSCT and lung transplant."
        },
        {
          "type": "paragraph",
          "text": "Retrospective multivariate analysis of aerosolized Ribavirin in HSCT patients indicates improved survival and reduced mortality, p <0,0001. Clin Infect Dis 57:1731, 2013. Benefit appears greater in preventing progression of upper tract disease to lower tract than in improving outcome in LRTI (reviewed in BMJ. 2019 Sep 10:366:15021). Oral ribavirin has been shown to be non-inferior and is dramatically less expensive: aerosolized ribavirin is no longer recommended. Clin Transplant. 2019 Sep;33(9):e13511; Transpl Infect Dis 2018 Apr;20(2):e12844; Clin Infect Dis 2019;68;1641"
        },
        {
          "type": "paragraph",
          "text": "Prevention:"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "components": [
              {
                "drug": "Nirsevimab (Beyfortus)",
                "notes": "single dose given soon after birth for all babies born October-March; single dose before RSV season for all babies born April-September"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "components": [
              {
                "drug": "Palivizumab (Synagis)",
                "dose": "15 mg/kg",
                "route": "IM",
                "frequency": "once per month November-April",
                "notes": "for specific infants who qualify for 5 doses (Pediatrics 124:1694, 2009) - Nirsvimab is preferred if available for lower cost, greater potency and increased convenience"
              }
            ]
          }
        },
        {
          "type": "paragraph",
          "text": "Timing of coverage may need to be adjusted in some regions based on reported cases in the region, as opposed to using fixed dosing schedules (Pediatrics 126:e116, 2010)."
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "paragraph",
      "text": "None"
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Antibiotics should be avoided in RSV infection and in bronchiolitis",
        "Aerosolized ribavirin is extremely expensive (~$50,000 US) and not recommended. Several studies suggest oral ribavirin is equivalent to inhaled and much less expensive (Clin Infect Dis 68:1641, 2019; Transpl Infect Dis 20:e12844, 2018;J Heart Lung Transplant. 2012 Aug;31(8):839-44).",
        "Nirsevimab is preferred if available for lower cost, greater potency and increased convenience. Palivizumab is very expensive and should only be used in patients who meet AAP recommendations (Pediatrics 2014:134 (2) 415-420) rather than the package insert. Timing and duration of prophylaxis vary with region and whether local RSV data are available. In phase 3 clinical trial, palivizumab decreased hospitalization but evidence review by the AAP concluded there is no impact on mortality and limited benefit on subsequent wheezing. (Pediatrics 2014;134:e620â€“e638)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Prevention"
    },
    {
      "type": "list",
      "items": [
        "Two RSV vaccines were FDA approved in May 2023 and are now available, notably in chain pharmacies.",
        "A single dose of Pfizer bivalent RSVpreF (Abrysvo) and GSK adjuvanted RSVPreF3 (Arexvy) vaccines each demonstrated significant efficacy against lower respiratory tract illness caused by RSV among older adults >60 years for at least two consecutive seasons.",
        "ACIP recommendations refer to RSV vaccination generically in persons >60 yrs, without differentiating one product from the other.",
        "For full information see RSV, Vaccine",
        "Only Abrysvo is FDA approved (August 2023) for maternal pre-natal vaccination at 32-36 wk gestation September-January in most of continental US to protect infants.",
        "ACIP has no preference between post-natal nirsevimab for infants or maternal Abrysvo but seasonality constrains Abrysvo.",
        "See Choice, Interchangeability on RSV, Vaccines.",
        "With Abyrsvo, despite concern during clinical trials, no increased risk of preterm birth based on maternal vaccination status in real-world use.",
        "Vaccinated 5.9% rate compared to unvaccinated 6.7% (JAMA Netw Open. 2024;7(7):e2419268).",
        "Concern exists over possible excess premature births in Abrysvo trials. Differences were small and not statistically significant but trial had limited power",
        "Considerations for choosing maternal Abrysvo (RSVPreF) vs. infant nirsevimab:"
      ]
    },
    {
      "type": "table",
      "tableData": {
        "headers": [
          "Abrysvo Potential Advantages",
          "Nirsevimab Potential Advantages"
        ],
        "rows": [
          [
            "Lower cost",
            "Longer protection"
          ],
          [
            "Activity at birth",
            "Very limited adverse effects"
          ],
          [
            "Theoretically higher barrier to resistance",
            "Pediatric providers are invested in immunization"
          ]
        ]
      }
    },
    {
      "type": "table",
      "tableData": {
        "headers": [
          "Abrysvo Potential Disadvantages",
          "Nirsevimab Potential Disadvantages"
        ],
        "rows": [
          [
            "Protection appears to wane after 3 months",
            "Higher cost"
          ],
          [
            "Limited to those 32-24 weeks just before or during RSV season",
            "Complicated re-imbursement in US based on VFC or commercial insurance"
          ],
          [
            "2-3 other vaccines recommended during pregnancy (COVID-19, TDaP, and influenza during season",
            "Need to determine maternal RSV vaccination history"
          ],
          [
            "Ob providers have not traditionally been vaccinators",
            ""
          ],
          [
            "Unresolved issue of prematurity",
            ""
          ],
          [
            "Coverage of other pregnancy vaccines is still low",
            ""
          ]
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "High cost, aerosol administration and potential toxicity limit use of aerosol ribavirin in HSCT patients.",
        "Two antiviral drugs highly effective in adult volunteers but development on hold during Phase 2-3 trials (GS 5806; N Engl J Med 371(8):711, 2014, Lumicitabine N Engl J Med 373(21):2048, 2015). New agents in development.",
        "New long acting monoclonal antibodies promise potential to reduce disease burden in healthy and high risk infants N Engl J Med 2022;386:837.",
        "Vaccines reduced medically attended lower respiratory tract disease and severe RSV in adults > 65 years by 80% N Engl J Med. 2023 Feb 16;388(7):595-608. review in N Engl J Med. 2023 Feb 16;388(7):579.",
        "Vaccination of pregnant women protects infants N Engl J Med 2023; 388(16):1451; JAMA. 2022 Dec 13;328(22):2201.",
        "Reference: immunocompromised hosts (Clin Infect Dis 56:258, 2013).",
        "Reference: adults (BMJ 2019 Sep 10;366:15021).",
        "Review of new strategies for older adults, pregnant people and infants. (Lancet Infect Dis,2023; 23, Issue 1, January, Pages e2)."
      ]
    }
  ]
}